scholarly journals The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer

2015 ◽  
Vol 42 (5) ◽  
pp. 458-464 ◽  
Author(s):  
Muyang Ding ◽  
Hang Zhang ◽  
Zhen Li ◽  
Cuili Wang ◽  
Jasmine Chen ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Therapeutic Target ◽  
Polycomb Group ◽  
Polycomb Group Protein ◽  
Enhancer Of Zeste ◽  
Group Protein ◽  
Novel Therapeutic

scholarly journals The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer

Oncotarget ◽  
2013 ◽  
Vol 4 (12) ◽  
pp. 2532-2549 ◽  
Author(s):  
Zhongwu Li ◽  
Yanling Wang ◽  
Jing Qiu ◽  
Qiang Li ◽  
Chunping Yuan ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Tongue Cancer ◽  
Polycomb Group ◽  
Polycomb Group Protein ◽  
Group Protein ◽  
Novel Therapeutic

scholarly journals Enhancer of Zeste Homolog 2 Overexpression Has a Role in the Development of Anaplastic Thyroid Carcinomas

2011 ◽  
Vol 96 (4) ◽  
pp. 1029-1038 ◽  
Author(s):  
Eleonora Borbone ◽  
Giancarlo Troncone ◽  
Angelo Ferraro ◽  
Zuzana Jasencakova ◽  
Lovorka Stojic ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Polycomb Group ◽  
Migration And Invasion ◽  
Polycomb Group Protein ◽  
Expression Levels ◽  
Thyroid Carcinomas ◽  
Enhancer Of Zeste ◽  
Pax8 Gene ◽  
Group Protein

Abstract Context: Enhancer of zeste homolog 2 (EZH2) is a histone lysine methyltransferase belonging to the polycomb group protein family. Overexpression of EZH2 has been found in several human malignancies including hematological and solid tumors. Objectives: In this study we investigated the expression levels of EZH2 and its polycomb group protein partners in thyroid carcinoma tissues with different degrees of malignancy to identify potential new therapeutic targets for anaplastic thyroid carcinoma (ATC). Results: We show that high EZH2 expression levels are characteristic of undifferentiated ATC, whereas no significant changes were observed in well-differentiated papillary and follicular thyroid carcinomas as compared with normal thyroid. Knockdown of EZH2 in ATC cell lines results in cell growth inhibition, loss of anchorage-independent growth, migration, and invasion properties. Moreover, we demonstrate that EZH2 directly controls differentiation of ATC cells by silencing the thyroid specific transcription factor paired-box gene 8 (PAX8). Conclusions: EZH2 is specifically overexpressed in ATC, and it directly contributes to transcriptional silencing of PAX8 gene and ATC differentiation.

Expression Profile of the Polycomb Group Protein Enhancer of Zeste Homologue 2 and its Prognostic Relevance in Renal Cell Carcinoma

2009 ◽  
Vol 182 (6) ◽  
pp. 2920-2925 ◽  
Author(s):  
Stefan Hinz ◽  
Steffen Weikert ◽  
Ahmed Magheli ◽  
Michèle Hoffmann ◽  
Rainer Engers ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Expression Profile ◽  
Renal Cell ◽  
Polycomb Group ◽  
Polycomb Group Protein ◽  
Prognostic Relevance ◽  
Enhancer Of Zeste ◽  
Group Protein

scholarly journals Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer

2012 ◽  
Vol 12 (1) ◽  
pp. 728-736 ◽  
Author(s):  
NATALIA MARYAN ◽  
MALGORZATA STATKIEWICZ ◽  
MICHAL MIKULA ◽  
KRZYSZTOF GORYCA ◽  
AGNIESZKA PAZIEWSKA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Polycomb Group ◽  
Polycomb Group Protein ◽  
Enhancer Of Zeste ◽  
Group Protein

Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients

The Prostate ◽  
2004 ◽  
Vol 60 (4) ◽  
pp. 273-281 ◽  
Author(s):  
Rika Ogata ◽  
Satoko Matsueda ◽  
Akihisa Yao ◽  
Masanori Noguchi ◽  
Kyogo Itoh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Polycomb Group ◽  
Polycomb Group Protein ◽  
Enhancer Of Zeste ◽  
Group Protein
Sign in / Sign up

Export Citation Format

Share Document